The tuberculosis-associated immune reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research

Purpose of review Antiretroviral therapy (ART) is an essential, life-saving intervention for HIV infection. However, ART initiation is frequently complicated by the tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) in TB endemic settings. Here, we summarize the current understanding highlighting the recent evidence. Recent findings The incidence of paradoxical TB-IRIS is estimated at 18% (95% CI 16–21%), higher than previously reported and may be over 50% in high-risk groups. Early ART initiation in TB patients increases TB-IRIS risk by greater than two-fold, but is critical in TB patients with CD4 counts less than 50 cells/&mgr;l because it improves survival. There remains no validated diagnostic test for TB-IRIS, and biomarkers recently proposed are not routinely used. Prednisone initiated alongside ART in selected patients with CD4 less than 100 cells/&mgr;l reduced the risk of paradoxical TB-IRIS by 30% in a recent randomized-controlled trial (RCT) and was not associated with significant adverse effects. Effective also for treating paradoxical TB-IRIS, corticosteroids remain the only therapeutic intervention for TB-IRIS supported by RCT trial data. TB-IRIS pathogenesis studies implicate high antigen burden, innate immune cell cytotoxicity, inflammasome activation and dysregulated matrix metalloproteinases in the development of the condition. Summary Specific biomarkers would aid in identifying high-risk patients for interventions and a diagnostic test is needed. Clinicians should consider prednisone for TB-IRIS prevention in selected patients. Future research should focus on improving diagnosis and investigating novel therapeutic interventions, especially for patients in whom corticosteroid therapy is contraindicated.

[1]  S. Swaminathan,et al.  Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial , 2018, JAMA internal medicine.

[2]  Joshua S. Davis,et al.  Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection , 2018, Open forum infectious diseases.

[3]  A. Hill,et al.  Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials , 2017, Current opinion in HIV and AIDS.

[4]  Irene N Njuguna,et al.  Urgent Versus Post-Stabilization Antiretroviral Treatment (ART) in Hospitalized Children: A Randomized Controlled Trial , 2017, The lancet. HIV.

[5]  R. Wilkinson,et al.  Neutrophil Activation and Enhanced Release of Granule Products in HIV-TB Immune Reconstitution Inflammatory Syndrome , 2017, Journal of acquired immune deficiency syndromes.

[6]  K. Maitland,et al.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa , 2017, The New England journal of medicine.

[7]  J. M. Peyper,et al.  Matrix Degradation in Human Immunodeficiency Virus Type 1–Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  R. Wilkinson,et al.  Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis , 2016, The Journal of infectious diseases.

[9]  Aman Sharma,et al.  Bevacizumab for paradoxical worsening treatment adjunct in HIV patient with choroidal tuberculoma , 2016, Journal of Ophthalmic Inflammation and Infection.

[10]  C. Locht,et al.  Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda , 2016, Journal of acquired immune deficiency syndromes.

[11]  R. Garg,et al.  Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis , 2016, BMC Infectious Diseases.

[12]  B. Chain,et al.  In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis , 2016, PLoS pathogens.

[13]  S. Madhi,et al.  Paradoxical tuberculosis‐associated immune reconstitution inflammatory syndrome in children , 2016, Pediatric pulmonology.

[14]  A. Fauci,et al.  A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Lederman,et al.  Vitamin D, d-dimer, Interferon γ, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study☆ , 2016, EBioMedicine.

[16]  D. Weissman,et al.  Matrix Metalloproteinases in Tuberculosis-Immune Reconstitution Inflammatory Syndrome and Impaired Lung Function Among Advanced HIV/TB Co-infected Patients Initiating Antiretroviral Therapy , 2015, EBioMedicine.

[17]  R. Wilkinson,et al.  HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome , 2015, Seminars in Immunopathology.

[18]  J. Banchereau,et al.  HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling , 2015, Nature Communications.

[19]  S. Abay,et al.  The Effect of Early Initiation of Antiretroviral Therapy in TB/HIV-Coinfected Patients , 2015, Journal of the International Association of Providers of AIDS Care.

[20]  R. Colebunders,et al.  Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome , 2015, PloS one.

[21]  J. Nachega,et al.  Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis , 2015, Annals of Internal Medicine.

[22]  R. Wilkinson,et al.  Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. , 2015, Future microbiology.

[23]  O. Lortholary,et al.  Anti-tumor necrosis factor monoclonal antibody for steroid-dependent TB-IRIS in AIDS. , 2015, AIDS.

[24]  L. Lindquist,et al.  Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial , 2015, PloS one.

[25]  D. Weissman,et al.  Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study. , 2015, The Lancet. Infectious diseases.

[26]  M. Noursadeghi,et al.  Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  S. Swaminathan,et al.  Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome , 2015, AIDS.

[28]  V. Haridas,et al.  TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB , 2015, AIDS.

[29]  G. Besra,et al.  Cytotoxic Mediators in Paradoxical HIV–Tuberculosis Immune Reconstitution Inflammatory Syndrome , 2015, The Journal of Immunology.

[30]  J. Crump,et al.  Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study , 2015, BMC Infectious Diseases.

[31]  M. Lederman,et al.  Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. , 2014, The lancet. HIV.

[32]  C. Delaugerre,et al.  Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. , 2014, The Lancet. Infectious diseases.

[33]  A. Sher,et al.  Role of IL-6 in Mycobacterium avium–Associated Immune Reconstitution Inflammatory Syndrome , 2014, The Journal of Immunology.

[34]  G. Maartens,et al.  Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome , 2013, European journal of immunology.

[35]  D. Boulware,et al.  Central Nervous System Immune Reconstitution Inflammatory Syndrome , 2013, Current Infectious Disease Reports.

[36]  L. Haddow,et al.  Incidence, Clinical Spectrum, Risk Factors and Impact of HIV-Associated Immune Reconstitution Inflammatory Syndrome in South Africa , 2012, PloS one.

[37]  G. Maartens,et al.  Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  D. Scott‐Algara,et al.  Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. , 2012, Blood.

[39]  R. Wilkinson,et al.  Immunological characterisation of an unmasking TB-IRIS case. , 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[40]  L. Montaner,et al.  Natural Killer Cell Activation Distinguishes Mycobacterium tuberculosis–Mediated Immune Reconstitution Syndrome From Chronic HIV and HIV/MTB Coinfection , 2011, Journal of acquired immune deficiency syndromes.

[41]  J. Flynn,et al.  Simian Immunodeficiency Virus-Induced Changes in T Cell Cytokine Responses in Cynomolgus Macaques with Latent Mycobacterium tuberculosis Infection Are Associated with Timing of Reactivation , 2011, The Journal of Immunology.

[42]  Y. Manabe,et al.  Antiretroviral Treatment-Associated Tuberculosis in a Prospective Cohort of HIV-Infected Patients Starting ART , 2010, Clinical & developmental immunology.

[43]  G. Maartens,et al.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome , 2010, AIDS.

[44]  K. Lacombe,et al.  Risk factors for ‘unmasking immune reconstitution inflammatory syndrome’ presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients , 2010, AIDS.

[45]  Timothy J. Sturgeon,et al.  Reactivation of Latent Tuberculosis in Cynomolgus Macaques Infected with SIV Is Associated with Early Peripheral T Cell Depletion and Not Virus Load , 2010, PloS one.

[46]  G. Maartens,et al.  Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  T. Sterling,et al.  Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. , 2009, The Journal of infectious diseases.

[48]  J. Baalwa,et al.  Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. , 2008, African health sciences.

[49]  P. Reiss,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.

[50]  S. Lawn,et al.  Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. , 2008, American journal of respiratory and critical care medicine.

[51]  C. Feldman,et al.  Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study , 2008, AIDS.

[52]  M. Johnson,et al.  Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? , 2005, AIDS.

[53]  C. F. von Reyn,et al.  High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  C. Kapelios,et al.  Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). , 2017, Current HIV research.

[55]  M. Lederman,et al.  A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study. , 2014, The lancet. HIV.